NCT05967884 2023-08-01
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
Ottawa Hospital Research Institute
Phase 2 Unknown
Clinical Trials
3 trialsNCT03736967 2021-11-01
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03886493 2021-10-15
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated